The plan – backed with a £2 billion ($2.68 billion) funding pledge – revolves around three overarching objectives, namely ...

Just over two years into Anderson's tenure, Bayer's board has decided to extend his contract by three years to 31st March, 2029, with company chairman Norbert Winkeljohann saying: "We're starting to ...

An antibody being developed by AstraZeneca for the treatment of light chain (AL) amyloidosis has failed to move the needle in ...

Healthinote is a smartphone-based toolkit designed to boost patient engagement by providing personalised, trustworthy, and ...

Novartis has another phase 3 trial win in its quiver for targeted factor B inhibitor iptacopan, building the case for the drug as a new oral therapy for diseases caused by disorders of the ...

The readout is particularly welcome for AZ as baxdrostat (formerly CIN-107) showed mixed results in earlier hypertension ...

The UK Biobank has completed the world's largest whole body imaging project, compiling more than a billion scans from 100,000 ...

Sanofi has been granted a speedy review from the FDA for a gene therapy for geographic atrophy (GA), a complication of age-related macular degeneration (AMD), as it prepares to test it in a clinical ...

A series of adverts for weight-loss services have been banned by the Advertising Standards Authority in the UK for promoting ...

Hong Kong-based Sino Biopharm, which took its stake in LaNova when it participated in the company's $42 million financing ...

A new formulation of Novartis' antimalarial Coartem has become the first medicine to be approved for use in very young ...

"Given the Supreme Court's ruling, HHS is now permitted to move forward with a portion of its RIF. Accordingly, you are ...